alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 or 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         DATE OF REPORT (Date of earliest event reported): July 24, 2003

                       SPAN-AMERICA MEDICAL SYSTEMS, INC.
                       ----------------------------------
             (Exact name of registrant as specified in its charter)

                         Commission File Number 0-11392

         South Carolina                                    57-0525804
(State or other jurisdiction of                (IRS Employer Identification No.)
 incorporation or organization)

                               70 Commerce Center
                        Greenville, South Carolina 29615
                        --------------------------------
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number (including area code): (864) 288-8877

                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)
<PAGE>

Item 7. Financial Statements and Exhibits.

(c)   Exhibits.

      Exhibit Number          Exhibit
      --------------          -------
      99.1                    Press Release dated July 24, 2003

Item 9. Regulation FD Disclosure/Results of Operations and Financial Condition.

On July 24, 2003, Span-America Medical Systems, Inc. ("SPAN") issued a press
release announcing financial information for its fiscal third quarter ended June
28, 2003. The press release is attached as Exhibit 99.1 to this Form 8-K and is
furnished to, but not filed with, the Commission. This information is provided
under Item 12 of Form 8-K.
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                         SPAN-AMERICA MEDICAL SYSTEMS, INC.

                                         /s/ Richard C. Coggins
                                         ------------------------------------
                                         Richard C. Coggins
                                         Chief Financial Officer

Dated: July 24, 2003
<PAGE>

                                INDEX TO EXHIBITS


Exhibit Number       Exhibit
--------------       -------
99.1                 Press Release dated July 24, 2003 *

*     This exhibit is furnished to, but not filed with, the Commission by
      inclusion herein.
Exhibit 31.2
  Certification
    1.
    I have reviewed this annual report on
    Form 10-K
    of AXS-One Inc.;  2.
    Based on my knowledge, this report does not contain any untrue
    statement of a material fact or omit to state a material fact
    necessary to make the statements made, in light of the
    circumstances under which such statements were made, not
    misleading with respect to the period covered by this report;3.
    Based on my knowledge, the financial statements, and other
    financial information included in this report, fairly present in
    all material respects the financial condition, results of
    operations and cash flows of the registrant as of, and for, the
    periods presented in this report;4.
    The registrants other certifying officer(s) and I are
    responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act
    Rules 13a-15(e)
    and
    15d-15(e))
    and internal control over financial reporting (as defined in
    Exchange Act Rules
    13a-15(f)
    and
    15d-15(f))
    for the registrant and have:          5.
    The registrants other certifying officer(s) and I have
    disclosed, based on our most recent evaluation of internal
    control over financial reporting, to the registrants
    auditors and the audit committee of the registrants board
    of directors (or persons performing the equivalent functions):      Date:  April 13, 2009

/s/  Joseph
    P. DwyerJoseph P. Dwyer
    Executive Vice President, Chief Financial Officer,
    and Treasurer
# C_2016016EN.01003301.xml

| 18.1.2016 | EN | Official Journal of the European Union | C 16/33 |
| --- | --- | --- | --- |

18.1.2016

EN

Official Journal of the European Union

C 16/33

---

Judgment of the General Court of 25 November 2015 — Sephora v OHIM — Mayfield Trading (Representation of two undulating vertical lines)

(Case T-320/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community figurative mark representing two undulating vertical lines - National and international figurative marks representing an undulating vertical line - Absolute ground for refusal - Lack of likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2016/C 016/40)

Language of the case: Spanish

Parties

Parties

Applicant: Sephora (Boulogne-Billancourt, France) (represented by: H. Delabarre, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: V. Melgar, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court: Mayfield Trading Ltd (Las Vegas, Nevada, United States of America) (represented by: A. Tarí Lázaro, lawyer)

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 24 February 2014 (Case R 1577/2013-4) relating to opposition proceedings between Sephora and Mayfield Trading Ltd.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Sephora to pay the costs. |
| --- | --- |

2.

Orders Sephora to pay the costs.

---

(1)  OJ C 212, 7.7.2014.

1

---
<PAGE>   1
                                                                    EXHIBIT 23.2

                        Consent of Independent Auditors


We consent to the reference to our firm under the caption "Experts", "Summary of
Financial Data" and "Selected Financial Data" and to the use of our report
dated March 16, 1999, with respect to the consolidated financial statements of
The Ackerley Group, Inc. and our report dated April 12, 1999, with respect to
the financial statements of WOKR(TV) included in the Registration Statement
(Form S-3 No. 333-49711) and related Prospectus of The Ackerley Group, Inc. for
the registration of 4,830,000 shares of its common stock.


                                                           /s/ Ernst & Young LLP


Seattle, Washington
July 9, 1999
# C_2014421EN.01006302.xml

| 24.11.2014 | EN | Official Journal of the European Union | C 421/63 |
| --- | --- | --- | --- |

24.11.2014

EN

Official Journal of the European Union

C 421/63

---

Action brought on 17 September 2014 — ZZ v ECB

(Case F-95/14)

2014/C 421/93

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: L. Levi and M. Vandenbussche, lawyers)

Applicant:

Defendant: European Central Bank

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision of the Executive Board of the ECB not to grant the applicant an additional salary increase, in the context of the annual revision of salaries and bonuses for 2014.

Form of order sought

Form of order sought

| — | Annul the decision of the Executive Board, adopted on 25 February 2014 and notified to the staff on 3 Mars 2014, not to grant the applicant an additional increase in salary for 2014; |
| --- | --- |

—

Annul the decision of the Executive Board, adopted on 25 February 2014 and notified to the staff on 3 Mars 2014, not to grant the applicant an additional increase in salary for 2014;

| — | annul the decision dismissing the special appeal dated 1July 2014 and received on 8 July 2014; |
| --- | --- |

—

annul the decision dismissing the special appeal dated 1July 2014 and received on 8 July 2014;

| — | if necessary, annul the decision of the competent Head of Department/DG-H not to consider or propose the applicant for an Additional Salary Increase, notified implicitly by the decision of the Executive Board of 25 February 2014 and by the decision to dismiss the special appeal of 1 July 2014; |
| --- | --- |

—

if necessary, annul the decision of the competent Head of Department/DG-H not to consider or propose the applicant for an Additional Salary Increase, notified implicitly by the decision of the Executive Board of 25 February 2014 and by the decision to dismiss the special appeal of 1 July 2014;

| — | order compensation for the material damage consisting of the loss of an opportunity to obtain an Additional Salary Increase in 2014, evaluated at EUR 54  635 or alternatively annulment of the procedure leading up to the decision of 25 February 2014 and the organisation by the ECB of a new procedure for granting additional salary increases for 2014; |
| --- | --- |

—

order compensation for the material damage consisting of the loss of an opportunity to obtain an Additional Salary Increase in 2014, evaluated at EUR 54  635 or alternatively annulment of the procedure leading up to the decision of 25 February 2014 and the organisation by the ECB of a new procedure for granting additional salary increases for 2014;

| — | order the defendant to pay compensation for the non-material damage suffered, assessed ex aequo et bono at EUR 5  000; |
| --- | --- |

—

order the defendant to pay compensation for the non-material damage suffered, assessed ex aequo et bono at EUR 5  000;

| — | order the ECB to pay the all the costs. |
| --- | --- |

—

order the ECB to pay the all the costs.

---
I 

118TH CONGRESS 

2D SESSION H. R. 7836 

To amend the Harmonized Tariff Schedule of the United States to provide 

for permanent duty-free treatment on imports of basketballs. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 29, 2024 

Mr. GUTHRIE introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL 

To amend the Harmonized Tariff Schedule of the United 

States to provide for permanent duty-free treatment on 

imports of basketballs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PERMANENT DUTY-FREE TREATMENT ON IM4 PORTS OF BASKETBALLS. 

5 (a) IN GENERAL.—Chapter 95 of the Harmonized 

6 Tariff Schedule of the United States is amended by insert7 ing in numerical sequence the following new subheading, 

8 with the article description having the same degree of in9 dentation as the article description for subheading 

10 9506.62.40: 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7836 IH

‘‘9506.62.70 Basketballs Free ................................................. 30%’’. 

1 (b) CONFORMING AMENDMENTS.— 

2 (1) Chapter 95 of the Harmonized Tariff 

3 Schedule of the United States, as amended by sub4 section (a), is further amended by redesignating sub5 heading 9506.62.80 as subheading 9506.62.81. 

6 (2) Subchapter II of chapter 99 of the Har7 monized Tariff Schedule of the United States is 

8 amended by striking headings 9902.17.75, 

9 9902.17.76, and 9902.17.77. 

10 (3) Note 20(s)(i) to subchapter III of chapter 

11 99 of the Harmonized Tariff Schedule of the United 

12 States is amended by striking ‘‘9506.62.80’’ and by 

13 inserting ‘‘9506.62.70’’ and ‘‘9506.62.81’’. 

14 (c) EFFECTIVE DATE.—The amendment made by 

15 subsection (a) applies to articles entered, or withdrawn 

16 from warehouse for consumption, on or after the 15th day 

17 after the date of the enactment of this Act. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1540 Galvanic skin response measurement device. ( a ) *Identification.* A galvanic skin response measurement device is a device used to determine autonomic responses as psychological indicators by measuring the electrical resistance of the skin and the tissue path between two electrodes applied to the skin.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 882.9.
[44 FR 51730, Sept. 4, 1979, as amended at 84 FR 71815, Dec. 30, 2019]
[Federal Register Volume 75, Number 44 (Monday, March 8, 2010)]
[Notices]
[Pages 10476-10477]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4814]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Interim Change to the Military Freight Traffic Unified Rules 
Publication (MFTURP) No. 1

AGENCY: Department of the Army, DoD.
SUMMARY: The Military Surface Deployment and Distribution Command 
(SDDC) is providing notice that it released an interim change to the 
MFTURP No. 1 on February 17, 2010. The interim change removes Motor 
Surveillance Service (MVS) from Item 107 and replaces Item 107 with 
Trailer Tracking Service (DCS). The change also updates Item 111, 
Satellite Motor Surveillance Service (SNS).

ADDRESSES: Submit comments to Publication and Rules Manager, Strategic 
Business Directorate, Business Services, 661 Sheppard Place, Attn: 
SDDC-OPM, Fort Eustis, VA 23604-1644. Request for additional 
information may be sent by e-mail to: <a href="/cdn-cgi/l/email-protection#a6c5cec7c288d288d6d4cfd0c3d2d2e6d3d588c7d4cbdf88cbcfca"><span class="__cf_email__" data-cfemail="fc9f949d98d288d28c8e958a998888bc898fd29d8e9185d2919590">[email protected]</span></a>.

FOR FURTHER INFORMATION CONTACT: Mr. Chad Privett, (757) 878-8161.

SUPPLEMENTARY INFORMATION:
    Reference: Military Freight Traffic Unified Rules Publications 
(MFTURP) No. 1.
    Background: The MFTURP No. 1 governs the purchase of surface 
freight transportation in the Continental United States (CONUS) by DoD 
using Federal Acquisition Regulation (FAR) exempt transportation 
service contracts.
    Motor Surveillance Service (MVS) has been removed from the MFTURP-1 
because it is a Transportation Protective Service (TPS) that is no 
longer used.
    Trailer Tracking Service (DCS) is a new TPS that augments Satellite 
Monitoring Service (SNS) for Security Risk Category (SRC) I-IV motor 
shipments travelling via closed-box-van trailers. SNS only allows the 
Defense Transportation Tracking System (DTTS) to track a Transportation 
Service Provider's (TSP) tractor. With the addition of DCS, DTTS will 
now be alerted if the closed-box-van trailer has been unhooked from the 
tractor or if the trailer's door has been opened while in transit.
    The Satellite Motor Surveillance Service verbiage has been updated 
in order to reflect current SNS operating procedures.
    Miscellaneous: This publication, as well as the other SDDC 
publications, can be accessed via the SDDC Web site at: http://
www.sddc.army.mil/Public/

[[Page 10477]]

Global%20Cargo%20Distribution/Domestic/Publications/.

C.E. Radford, III,
Division Chief, G9, Strategic Business Directorate.
[FR Doc. 2010-4814 Filed 3-5-10; 8:45 am]
BILLING CODE 3710-08-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
I 

### I

fl ’ ! 34 

# ) / Atton

I ! RTTTOFSEY EENmPINIONS 5124k32116 I

;nccal Opinion O-749 at issued
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4371 Irrigating wound retractor device. ( a ) *Identification.* An irrigating wound retractor device is a prescription device intended to be used by a surgeon to retract the surgical incision, to provide access to the surgical wound, to protect and irrigate the surgical wound, and to serve as a conduit for removal of fluid from the surgical wound.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The patient-contacting components of the device must be demonstrated to be biocompatible and evaluated for particulate matter.
( 2 ) Performance data must demonstrate the sterility and pyrogenicity of the patient-contacting components of the device.
( 3 ) Performance data must support shelf life by demonstrating continued functionality and sterility of the device over the identified shelf life.
( 4 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Performance testing must: ( i ) Characterize the tear resistance, tensile strength, and elongation properties of the barrier material;
( ii ) Demonstrate that the liquid barrier material is resistant to penetration by blood, and is non-flammable;
( iii ) Characterize the forces required to deploy the device;
( iv ) Characterize the device's ranges of operation, including flow rates and maximum suction pressures;
( v ) Demonstrate the ability of the device irrigation apparatus to maintain a user defined or preset flow rate to the surgical wound; and
( vi ) Demonstrate the ability of the device to maintain user defined or preset removal rates of fluid from the surgical wound.
( 5 ) The labeling must include or state the following information: ( i ) Device size or incision length range;
( ii ) Method of sterilization;
( iii ) Flammability classification;
( iv ) Non-pyrogenic;
( v ) Shelf life; and
( vi ) Maximum flow rate and suction pressure.
[83 FR 24, Jan. 2, 2018]
```

[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10245]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4622]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER10-726-000]

DPL Energy Resources, Inc.; Supplemental Notice That Initial 
Market-Based Rate Filing Includes Request For Blanket Section 204 
Authorization

February 26, 2010.
    This is a supplemental notice in the above-referenced proceeding of 
DPL Energy Resources, Inc.'s application for market-based rate 
authority, with an accompanying rate tariff, noting that such 
application includes a request for blanket authorization, under 18 CFR 
Part 34, of future issuances of securities and assumptions of 
liability.
    Any person desiring to intervene or to protest should file with the 
Federal Energy Regulatory Commission, 888 First Street, NE., 
Washington, DC 20426, in accordance with Rules 211 and 214 of the 
Commission's Rules of Practice and Procedure (18 CFR 385.211 and 
385.214). Anyone filing a motion to intervene or protest must serve a 
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with 
regard to the applicant's request for blanket authorization, under 18 
CFR Part 34, of future issuances of securities and assumptions of 
liability, is March 18, 2010.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet 
access who will eFile a document and/or be listed as a contact for an 
intervenor must create and validate an eRegistration account using the 
eRegistration link. Select the eFiling link to log on and submit the 
intervention or protests.
    Persons unable to file electronically should submit an original and 
14 copies of the intervention or protest to the Federal Energy 
Regulatory Commission, 888 First Street, NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in 
the Commission's eLibrary system by clicking on the appropriate link in 
the above list. They are also available for review in the Commission's 
Public Reference Room in Washington, DC. There is an eSubscription link 
on the Web site that enables subscribers to receive e-mail notification 
when a document is added to a subscribed docket(s). For assistance with 
any FERC Online service, please e-mail [email protected]. or 
call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Kimberly D. Bose,
Secretary.
[FR Doc. 2010-4622 Filed 3-4-10; 8:45 am]
BILLING CODE 6717-01-P
```
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3 Effective dates of requirement for premarket approval. A device included in this part that is classified into class III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the device unless the manufacturer has an approval under section 515 of the act (unless an exemption has been granted under section 520(g)(2) of the act). An approval under section 515 of the act consists of FDA's issuance of an order approving an application for premarket approval (PMA) for the device or declaring completed a product development protocol (PDP) for the device. ( a ) Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a device that has been found substantially equivalent to such a device, has an approval under section 515 of the act FDA must promulgate a regulation under section 515(b) of the act requiring such approval, except as provided in paragraph (b) of this section. Such a regulation under section 515(b) of the act shall not be effective during the grace period ending on the 90th day after its promulgation or on the last day of the 30th full calendar month after the regulation that classifies the device into class III is effective, whichever is later. See section 501(f)(2)(B) of the act. Accordingly, unless an effective date of the requirement for premarket approval is shown in the regulation for a device classified into class III in this part, the device may be commercially distributed without FDA's issuance of an order approving a PMA or declaring completed a PDP for the device. If FDA promulgates a regulation under section 515(b) of the act requiring premarket approval for a device, section 501(f)(1)(A) of the act applies to the device.
( b ) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified. If FDA knows that a device being commercially distributed may be a “new” device as defined in this section because of any new intended use or other reasons, FDA may codify the statutory classification of the device into class III for such new use. Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.